Search Clinical Trials in the European Union
Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2661-2680 of 3,900 trials
Appendicitis>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyInfectious DiseasesOrthopedics and Traumatology
Neuromuscular ScoliosisAdolescent Idiopathic Scoliosis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOrthopedics and TraumatologyPediatrics
Inflammatory Dilated Cardiomyopathy>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesCardiologyInternal Medicine
Unresectable Soft-Tissue Sarcoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology
Head and Neck Squamous Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology
Acute Myeloid LeukemiaMyelodysplastic Syndromes>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology
Pemphigus Diseases>2 yearsMonitoring phase (IV)>20 visitsNo PlaceboStandard MedicinesDermatologyRheumatology
High Potassium Levels>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyInternal Medicine
Diarrhea Predominant Irritable Bowel Syndrome≤3 monthsMonitoring phase (IV)≤5 visitsInvestigational MedicinesGastroenterologyInternal Medicine
Gram-negative Bacteremia3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine
Double Diabetes6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteDiabetologyEndocrinology
Hepatocellular Carcinoma (HCC)>2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHepatologyOncology
Respiratory Distress>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard Medicines
Pancreatic Fistula≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine
Gastrointestinal Stromal Tumor (GIST)1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyOncology